Serina Therapeutics Inc (SER) Stock Analysis

AI analysis of Serina Therapeutics Inc (SER)

Buy

Serina Therapeutics Inc is a good buy right now due to its recent positive developments and potential for growth. The stock is currently priced at $1.85, significantly below its 52-week high of $4.99, indicating a potential upside. Additionally, the RSI is at 56.234, suggesting that the stock is not overbought, which is favorable for entry. The recent partnership with Gannet BioChem and FDA approval for SER-252 could drive future growth, with analysts projecting a price target of $8, which represents a potential upside of over 300%. However, the main risk is the negative earnings trend, with a reported EPS of -0.58 in the last quarter, indicating ongoing financial challenges.

Valuation Metrics

The current forward P/E ratio for Serina Therapeutics Inc (SER) is 0.00, compared to its 5-year average forward P/E of -1.32.

Forward P/E

Fair

5Y Average P/E

-1.32

Current P/E

0.00

Overvalued

0.14

Undervalued

-2.77

Forward EV/EBITDA

Strongly Undervalued

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued

0.00

Undervalued

0.00

Forward P/S

Strongly Undervalued

5Y Average P/S

0.00

Current P/S

0.00

Overvalued

0.00

Undervalued

0.00

Alphio AI Price Scenarios for SER

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%SER

$6.43

Scenario price

B

Base

Base · 50%SER

$5.16

Scenario price

B

Bear

Bear · 25%SER

$4.51

Scenario price

Whales holding SER

B

Broadwood Capital, Inc.

+ HoldingSER

-0.01%

3M Return

SER FAQ — answered by Alphio AI

Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Serina Therapeutics Inc is a good buy right now due to its recent positive developments and potential for growth. The stock is currently priced at $1.85, significantly below its 52-week high of $4.99, indicating a potential upside. Additionally, the RSI is at 56.234, suggesting that the stock is not overbought, which is favorable for entry. The recent partnership with Gannet BioChem and FDA approval for SER-252 could drive future growth, with analysts projecting a price target of $8, which represents a potential upside of over 300%. However, the main risk is the negative earnings trend, with a reported EPS of -0.58 in the last quarter, indicating ongoing financial challenges.